513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
T-Dxd Ovarian Cancer	AstraZeneca	P1/2	CC (40)
Ter-2013 Ovarian Cancer	Terremoto Biosciences Inc.	P1/2	CC (40)
tng348 Ovarian Cancer	Tango Therapeutics, Inc.	P1/2	CC (40)
Torvutatug Samrotecan Ovarian Cancer	AstraZeneca	P1/2	CC (40)
Trop2-Car-Nk Ovarian Cancer	M.D. Anderson Cancer Center	P1/2	CC (40)
tt-10 Ovarian Cancer	Portage Biotech	P1/2	CC (40)
tt-4 Ovarian Cancer	Portage Biotech	P1/2	CC (40)
Tub-040 Ovarian Cancer	Tubulis GmbH	P1/2	CC (40)
Vofatamab Ovarian Cancer	Fusion Pharmaceuticals Inc.	P1/2	CC (40)
xnw27011 Ovarian Cancer	Evopoint Biosciences Inc.	P1/2	CC (40)
xnw28012 Ovarian Cancer	Evopoint Biosciences Inc.	P1/2	CC (40)
XS-02 Ovarian Cancer	NovaOnco Therapeutics Co., Ltd.	P1/2	CC (40)
XYA02 Ovarian Cancer	XYone Therapeutics, Inc	P1/2	CC (40)
Alectinib Ovarian Cancer	OHSU Knight Cancer Institute	Early P1	C (39)
b7h3 car-γδt cells Ovarian Cancer	Peking University	Early P1	C (39)
Berzosertib Ovarian Cancer	EMD Serono Research & Development Institute, Inc.	P1	C (39)
Capivasertib Ovarian Cancer	M.D. Anderson Cancer Center	P1	C (39)
Cdx-585 Ovarian Cancer	Celldex Therapeutics	P1	C (39)
Cnsi-Fe Ovarian Cancer	Sichuan Enray Pharmaceutical Sciences Company	P1	C (39)
Cue-102 Ovarian Cancer	Cue Biopharma	P1	C (39)
Eli-002 7P Ovarian Cancer	Elicio Therapeutics	P1	C (39)
Enoblituzumab Ovarian Cancer	Masonic Cancer Center, University of Minnesota	P1	C (39)
Hyaluronidase Zzxf Ovarian Cancer	OHSU Knight Cancer Institute	Early P1	C (39)
Kand145 Ovarian Cancer	Novakand Pharma AB	P1	C (39)
mb1707 Ovarian Cancer	Mainline Biosciences, Inc.	Early P1	C (39)
NC 410 Ovarian Cancer	NextCure, Inc.	P1/2	C (39)
pf-07257876 Ovarian Cancer	Pfizer	P1	C (39)
Ribociclib Ovarian Cancer	Blueprint Medicines Corporation	P1	C (39)
rp903 Ovarian Cancer	Risen (Suzhou) Pharma Tech Co., Ltd.	P1	C (39)
Vemurafenib Ovarian Cancer	OHSU Knight Cancer Institute	Early P1	C (39)
Zimberelimab Ovarian Cancer	Arcus Biosciences, Inc.	P1	C (39)
Immunoglobulin G1 [188,412-Bis[4-(Azidomethyl)-L-Phenylalanine]], Anti-(Human Folate Receptor ?) (Human-Mus Musculus Monoclonal Sp8166 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Sp8166 ?-Chain, Dimer, Click Reaction Product With 3-[[[[4-[[N-[4-(11,12-Didehydrodibenz[B,F]Azocin-5(6H)-Yl)-1,4-Dioxobutyl]-L-Valyl-N5-(Aminocarbonyl)-L-Ornithyl]Amino]Phenyl]Methoxy]Carbonyl]Amino]-N,?,?-Trimethyl-L-Phenylalanyl-N-[(1S,2E)-3-Carboxy-1-(1-Methylethyl)-2-Buten-1-Yl]-N,3-Dimethyl-L-Valinamide (1:4) Ovarian Cancer	Sutro Biopharma, Inc.	P1	C (38)
[177lu]lu-evs459 Ovarian Cancer	Novartis Pharmaceuticals	P1	C (36)
[68ga]ga-evs459 Ovarian Cancer	Novartis Pharmaceuticals	P1	C (36)
ab598 Ovarian Cancer	Arcus Biosciences, Inc.	P1	C (36)
Abbv-901 Ovarian Cancer	AbbVie	P1	C (36)
Amivantamab-Vmjw Ovarian Cancer	Fate Therapeutics	P1	C (36)
Amt-151 Ovarian Cancer	Multitude Therapeutics Inc.	P1	C (36)
Apg 2449 Ovarian Cancer	Ascentage Pharma Group Inc.	P1	C (36)
Arog4-01 Ovarian Cancer	Aromics Therapeutics	P1	C (36)
asp1893 Ovarian Cancer	Astellas Pharma Global Development, Inc.	P1	C (36)
Atv-1601 Ovarian Cancer	Atavistik Bio, Inc	P1	C (36)
Atx-295 Ovarian Cancer	Accent Therapeutics	P1	C (36)
Autologous, Engineered T Cells Targeting Tp53 R175H Ovarian Cancer	AstraZeneca	P1	C (36)
Autologous Genetically Modified Mage-A4ᶜ¹º³²T Cells Ovarian Cancer	USWM CT, LLC	P1	C (36)
azd5335 Ovarian Cancer	AstraZeneca	P1	C (36)
b7-h3cart Ovarian Cancer	Stanford University	P1	C (36)
Balstilimab Ovarian Cancer	Agenus Inc.	P1	C (36)
Bdc-3042 Ovarian Cancer	Bolt Biotherapeutics, Inc.	P1	C (36)
Bemarituzumab Ovarian Cancer	Centre Leon Berard	P1/2	C (36)

Showing 351 to 400 of 513 assets

PreviousPage 8 of 11Next